The Superior Chondrogenic Potential of Bone Marrow-Derived MSCs: A Comparative Study with Adipose Tissue and Wharton´s Jelly Sources

Technical Summary: The Superior Chondrogenic Potential of Bone Marrow-Derived MSCs

Problem Statement
Cartilage possesses a poor intrinsic healing capacity due to its avascular nature, low cell density (1–5% of tissue volume), and the tendency of chondrocytes to dedifferentiate in monolayer culture. While cell-free protocols like microfracture exist, they often result in the formation of suboptimal fibrocartilage. Cell therapy using mesenchymal stromal cells (MSCs) offers a promising alternative; however, the optimal source of MSCs for cartilage tissue engineering remains a subject of debate. Furthermore, standard culture media often rely on fetal bovine serum (FBS), which poses risks of disease transmission and immune reactions in human applications. Consequently, there is a need to identify the most responsive MSC source and evaluate the efficacy of human platelet lysate (hPL) as a safer, xeno-free alternative for inducing chondrogenesis.

Methodology
The study conducted a comparative analysis of human MSCs derived from three distinct sources: bone marrow (BM-MSCs), adipose tissue (AT-MSCs), and Wharton's jelly (WJ-MSCs).

• Scaffold and Culture: Cells were embedded in a rat collagen type I hydrogel (3.73 mg/mL) at a density of 1,000 cells/µL. This 3D environment was chosen to mimic tissue condensation and cell-to-cell contact, which are critical for chondrogenesis.
• Experimental Groups: Cells were cultured for 21 days under three conditions:
  1. Chondrogenic Medium (CH): Alpha MEM supplemented with TGF-β3, ITS, and L-ascorbic acid, containing either 1% or 5% hPL.
  2. Growth Medium (G): Alpha MEM supplemented with 5% hPL (serving as the control).
• Assessments:
  • Viability: Metabolic activity was measured via MTS assay (CellTiter 96) on Days 1, 7, and 21.
  • Gene Expression: Quantitative PCR (qPCR) was performed on Days 1, 14, and 21 to analyze mRNA levels of chondrogenic markers: Sox9 (early), Collagen type II (COL2A1, middle), and Aggrecan (ACAN, late).
  • Protein Deposition: Immunofluorescence staining was used on Day 21 to visualize Collagen type II deposition in the extracellular matrix (ECM).

Key Results

• Cell Viability: BM-MSCs exhibited significantly higher initial metabolic activity compared to AT-MSCs and WJ-MSCs. Over time, BM-MSCs in chondrogenic medium with 5% hPL showed the highest metabolic activity on Day 7, while those in 1% hPL showed the lowest. A general decline in absorbance was observed across all groups by Day 21, potentially linked to scaffold contraction and dye binding.
• Gene Expression:
  • BM-MSCs: Demonstrated the most robust response. Significant upregulation of Sox9, COL2A1, and Aggrecan was observed, particularly in the 1% hPL chondrogenic group. COL2A1 and Aggrecan expression in BM-MSCs was up to six orders of magnitude higher than in AT-MSCs or WJ-MSCs.
  • AT-MSCs: Showed some expression of chondrogenic markers, but significantly lower than BM-MSCs. Aggrecan expression was negligible or absent in most groups.
  • WJ-MSCs: Exhibited little to no expression of chondrogenic marker mRNA, with high sample variability.
• Protein Synthesis: Immunofluorescence confirmed that Collagen type II deposition was abundant and strong in BM-MSCs cultured in 1% hPL chondrogenic medium. AT-MSCs showed weak deposition, and WJ-MSCs showed only mild deposition in the 1% hPL group. No Collagen type II synthesis was detected in any growth medium (control) groups, likely due to the absence of ascorbate.

Key Contributions

1. Source Comparison: The study provides direct, head-to-head evidence that BM-MSCs possess superior innate responsiveness to chondrogenic signals compared to AT-MSCs and WJ-MSCs when cultured in a collagen type I hydrogel.
2. Optimization of hPL: The research identifies that reducing human platelet lysate concentration to 1% in chondrogenic medium enhances the expression of chondrogenic transcription factors (Sox9) and matrix proteins (Collagen II, Aggrecan) in BM-MSCs more effectively than 5% hPL. The authors suggest that lower hPL concentrations may reduce the interference of non-specific cytokines with TGF-β3 signaling.
3. Validation of 3D Culture: The study confirms that embedding MSCs in collagen type I hydrogel facilitates cell condensation and chondrogenic differentiation, although scaffold contraction remains a physical limitation.

Significance and Claims
The authors conclude that bone marrow-derived MSCs are the most suitable candidate for cartilage tissue engineering research and applications among the three sources tested. The study validates the use of a chondrogenic medium supplemented with 1% human platelet lysate as an effective, xeno-free protocol for inducing stable chondrogenesis in BM-MSCs.

The paper modestly notes that while the collagen type I gel promotes differentiation, its significant contraction limits its immediate utility as a standalone implant for filling defects. Therefore, the authors suggest that future work should focus on optimizing the hydrogel composition to prevent contraction while maintaining its chondrogenic potential. The study does not claim that WJ-MSCs or AT-MSCs are ineffective, but rather that their chondrogenic potential is distinctly inferior to that of BM-MSCs under the tested conditions.